Discover and read the best of Twitter Threads about #kras
Most recents (18)
1/3
@Fynnderella1 @53v3n0fn1n3 @DoorlessCarp
Here is a challenge for you brilliant minds:
Which one would you think would be more likely to deal with KRAS-mutations and also reballance micro RNAs?
ncbi.nlm.nih.gov/pmc/articles/P…
cell.com/molecular-ther…
ncbi.nlm.nih.gov/pmc/articles/P…
@Fynnderella1 @53v3n0fn1n3 @DoorlessCarp
Here is a challenge for you brilliant minds:
Which one would you think would be more likely to deal with KRAS-mutations and also reballance micro RNAs?
ncbi.nlm.nih.gov/pmc/articles/P…
cell.com/molecular-ther…
ncbi.nlm.nih.gov/pmc/articles/P…
3/3
Hm... Could one combine both to optimal stimulate/ reballance the MAPk , miRNA and the mTOR-complex?
ncbi.nlm.nih.gov/pmc/articles/P…
ncbi.nlm.nih.gov/pmc/articles/P… (2-4)
I wonder why ther seems to be no lecture about miR affected by IVM?
Hm... Could one combine both to optimal stimulate/ reballance the MAPk , miRNA and the mTOR-complex?
ncbi.nlm.nih.gov/pmc/articles/P…
ncbi.nlm.nih.gov/pmc/articles/P… (2-4)
I wonder why ther seems to be no lecture about miR affected by IVM?
The #AACR23 abstracts will be accessible from here (not all sessions populated yet at the time of this tweet)
abstractsonline.com/pp8/#!/10828/
abstractsonline.com/pp8/#!/10828/
"new drugs on the horizon":
ND03 - Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer $ARVN #PROTAC
abstractsonline.com/pp8/#!/10828/p…
ND03 - Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer $ARVN #PROTAC
abstractsonline.com/pp8/#!/10828/p…
ND01 - ABBV-319: A first-in-class Glucocorticoid Receptor Modulator (GRM) agonist #ADC for the treatment of B-cell malignancies $ABBV
abstractsonline.com/pp8/#!/10828/p…
abstractsonline.com/pp8/#!/10828/p…
1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress.
@myESMO #LCSM #FOAMed
@myESMO #LCSM #FOAMed
2) The faculty for this outstanding program were @peters_solange (Chair) 🇨🇭, @HosseinBorghaei 🇺🇸, Natasha Leighl MD 🇨🇦, and @dplanchard 🇫🇷. A truly international roster of experts in #oncology!
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
3) This program is supported by an educational grant from Sanofi. Statement of accreditation and author disclosures are at oncologytweetorials-ce.com/disclosures/.
There is a lot to consider in this first-line study of the #KRAS G12C inhibitor adagrasib plus pembrolizumab from #ESMOImmuno22. Some pleasant surprises in terms of safety. Definitely encouraging but need to see a bit more to be sold on this strategy. 🤔 #LCSM
We're looking for synergy with the two agents - more than an additive effect. Reason to believe there will be based on preclinical data showing the effect on T-cell infiltration from #KRAS inhibition. Similar to what has been shown with MEK inhibition. #ESMOImmuno22
The first-line dataset includes the phase Ib KRYSTAL-1 and the phase II KRYSTAL-7. In KRYSTAL-1 (n=7), 4/7 had a response and all were durable (>9m). G3 TRAEs in 4 pts (lipase elevation, LFTs, muscular pain, pneumothorax). #ESMOImmuno22
#KRAS alert! Over the past 4 years, a multi-disciplinary team from @hopkinskimmel @VUMC_Cancer @DanaFarber @MSKCancerCenter & @Amgen has been studying the distribution and co-mutations of KRAS, NRAS and HRAS mutant #cancers under the auspices of @AACR project #GENIE. Read the 🧵
Our work is now published online at @CR_AACR and represents the largest study of RAS genomic architecture to date, leveraging #NGS data from >600,000 mutations and >66,000 tumors across 51 #cancer types.
Full text here
aacrjournals.org/cancerres/arti….
Full text here
aacrjournals.org/cancerres/arti….
Our findings provide insights in the genomic architecture of RAS mutant cancers and may serve as a blueprint for mapping therapeutic vulnerabilities for mut RAS. Given the vast array of findings we have put together a shiny app for interactive #dataviz:
ras-hallmarks.jhmi.edu
ras-hallmarks.jhmi.edu
Oggi vi parlo di una bellissima scoperta di una proteina fondamentale per lo sviluppo del tumore al pancreas da uno studio tutto italiano pubblicato su Gastroenterology. Segue un thread da non perdere assolutamente. Let's go!
1/n 🧵#oncology #12febbraio
1/n 🧵#oncology #12febbraio
Il tumore al pancreas rimane a oggi uno dei tumori più letali e complessi da individuare: la scarsa percentuale di sopravvivenza è principalmente dovuta al fatto che la malattia, nelle sue fasi iniziali, non si manifesta con sintomi eclatanti. 2/n
Inoltre, la comprensione di tali fasi è ancora limitata, così come la conoscenza di marcatori molecolari per la diagnosi precoce. 3/n
$NVS R&D day slides
novartis.com/sites/novartis…
$SAN $SNY Vaccine day slides from yesterday
Part 1
sanofi.com/-/media/Projec…
Part 2
sanofi.com/-/media/Projec…
novartis.com/sites/novartis…
$SAN $SNY Vaccine day slides from yesterday
Part 1
sanofi.com/-/media/Projec…
Part 2
sanofi.com/-/media/Projec…
$NVS featured multi-b$ products
$NVS Strategy to 2026
main approvals by mkt potential & current "strength of evidence"
earlier stage pipe in pharmaceuticals & oncology
main approvals by mkt potential & current "strength of evidence"
earlier stage pipe in pharmaceuticals & oncology
1/12 #TumorBoardTuesday
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.
📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.
📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
2/12 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
Thurs Case🎀
Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
3/12
#TumorBoardTuesday
Thursday Case🎀
👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply
ALL CME 🔗: integrityce.com/tbt
#TumorBoardTuesday
Thursday Case🎀
👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply
ALL CME 🔗: integrityce.com/tbt
#APC #TumorBoardTuesday #GITwitter #LiverTwitter #PrecisionMedicine #ColonCancer #oncology @ASCO @TumorBoardTues @CCAlliance @GeneticsSociety #Genetics #Genomics
Many of the mutations happen in the MCR region, WE should investigate the Armadillo Repeats regions for therapeutics
Many of the mutations happen in the MCR region, WE should investigate the Armadillo Repeats regions for therapeutics
@curecc #ccfac2021 @noza512 @HopkinsMedicine presents on excitement about potential for peptide-based #vaccines as #immunotherapy for #cholangiocarcinoma ! Afterall, tumor recognition is king! And neoantigens critical...
@curecc #ccfac2021 @noza512 Combo approach of #neoantigen vaccine + #immunotherapy can be highly effective! But #cholangiocarcinoma has lower #neoantigen burden c/w other tumor, higher T cell exhaustion
@curecc #ccfac2021 @noza512 Trial soon to open...hope for opening for #cholangiocarcinoma in near future? Stay tuned!
#ESMO20 Well done discussion by Dr. Colin Lindsay who wins for most random @Twitter handle - @mylovelypinata. Helpful reminder of the journey leading to direct #KRAS inhibitors and the achievements of medicinal chemistry leading to agents like AMG 510 and MRTX849. #LCSM
#ESMO20 Sotorasib was safe and effective in #KRAS G12C NSCLC. Safety profile will allow for combinations: what are the right partners? Can we combine with IO? Do we need a phase III vs docetaxel? @mylovelypinata says absolutely, we do. And other KRAS mutations being targeted too!
#ESMO20 Commenting on CHRYSALIS - amivantamab and lazertinib was safe and effective in osi-resistant and naive populations. Too early for cross trial comparisons but it seems as though IV drugs for #EGFR NSCLC are back. #LCSM #OncoAlert
#ESMO20 Much anticipated results from CodeBreaK100: AMG 510 (sotorasib) in #KRAS G12C #NSCLC by @DavidHongMD building on exciting data seen over the past two years for this huge unmet need. #LCSM @OncoAlert @myESMO
#ESMO20 KRAS G12C occurs in 13% of NSCLC, 3-5% CRC, and other tumors as well. Up until recently, considered "undruggable". Sotorasib is a highly selective KRAS G12C inhibitor that traps KRAS in its inactive GDP bound state. #LCSM @OncoAlert
#ESMO20 CodeBreak100 is a phase I escalation/expansion trial of sotorasib monotherapy in KRAS G12C tumors. Primary endpoint was safety. Escalation established preferred dose of 960mg qday. #LCSM @OncoAlert
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
🇦🇺DYNAMIC-II
🇦🇺DYNAMIC-III
🇺🇸COBRA @NRGonc
🇺🇸BESPOKE
🇺🇸@SU2C
🇯🇵 CIRCULATE
🌎COLUMBIA
🇮🇹🇪🇸PEGASYS
🇬🇧TRACC
🇩🇪CIRCULATE
🇫🇷crEATE
🇩🇰IMPROVE-IT
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
What’s the difference between colon and lung? Not an easy question when it comes to #KRAS. Our work out today in @CD_AACR today describe a strategy to overcome resistance to KRAS G12C inhibition in CRC. @sloan_kettering @Albert0Bardelli @BardelliLab bit.ly/2ACWd7H👇👇👇
Molecular response to KRAS G12C inhibitors is different in CRC and NSCLC models. CRC models show quick MAPK pathway rebound
Receptor tyrosine kinases and EGFR dependency is stronger in CRC models
#DCLUNG19 Daunting task of all non-EGFR/ALK drivers in #NSCLC handled easily by @alexdrilon - in #ROS1, note that not all ALK inhibitors are ROS1 inhibitors. Variation in CNS activity. Many active drugs to consider. #LCSM #LCAM
#DCLUNG19 Highly active, CNS penetrant and well tolerated TKIs for #RET and #NTRK fusion positive cancers, outlined by expert @alexdrilon
#WCLC19 Potential target is mesothelin, enriches in advanced disease and #KRAS #NSCLC - note the antigen heterogeneity though. Challenge in CAR-T strategies. Preclinically, dependent on antigen density. In trials though, responses also seen with low expression. #OncoAlert
#WCLC19 Highly anticipated update on AMG510 in #KRAS #NSCLC by Ramaswamy Govindan does not disappoint. High RR (48%, 54% at 960mg) and DCR of 100%! No DLTs! Amazing early data in a huge area of need. #OncoAlert
#WCLC19 Swimmers plot for AMG510 shown here. Responses occur quickly. NOTE: not all of these responses are confirmed. Need to see how durable these are. Remember our experience with MEKi in #KRAS #NSCLC - RR nice but not durable (trametinib plot shown) #OncoAlert
Intriguing article in the June issue of @JTOonline by #JongWooLee and @DrRoyHerbstYale tackling the impact of #KRAS on the immune microenvironment in #NSCLC and the rationale for combining #MEK inhibition and anti-PD(L)1 therapy. #OncoAlert #LCSM
jto.org/article/S1556-…
jto.org/article/S1556-…
Authors induced a p53/KRAS G12D mutant NSCLC. Compared to tumor free lungs, see a stark increase in CD45+ cells. Note, geographically localized to periphery/margin. Translational challenge: easy to miss with biopsies(aspirates not helpful).
Specifically, there’s a rise in neutrophils and MDSCs and a decrease in CD3+/CD8+ T cells in the tumor bearing lung (red bars below). Accompanied by rise in PDL1 expression (in tumor and MDSCs). Story: does this immune cell accumulation precede tumor development? Is it required?
